Selected article for: "case case series and study design"
Author: Tobaiqy, Mansour; Qashqary, Mohammed; Al-Dahery, Shrooq; Mujallad, Alaa; Hershan, Almonther Abdullah; Kamal, Mohammad Azhar; Helmi, Nawal
Title: Therapeutic Management of COVID-19 Patients: A systematic review
  • Cord-id: uxl8liil
  • Document date: 2020_4_17
    • ID: uxl8liil
    Snippet: Abstract Background SARS-CoV-2 is the causative agent of COVID-19; that has been declared a global pandemic by the WHO in 2020. The COVID-19 treatment guidelines vary in each country, and yet there is no approved therapeutic for COVID-19. Aims of the study this review aimed to report any evidence of therapeutics used for the management of COVID-19 patients in clinical practice since the emergence of the virus. Methods A systematic review protocol was developed based on PRISMA Statement. Articles
    Document: Abstract Background SARS-CoV-2 is the causative agent of COVID-19; that has been declared a global pandemic by the WHO in 2020. The COVID-19 treatment guidelines vary in each country, and yet there is no approved therapeutic for COVID-19. Aims of the study this review aimed to report any evidence of therapeutics used for the management of COVID-19 patients in clinical practice since the emergence of the virus. Methods A systematic review protocol was developed based on PRISMA Statement. Articles for review were selected from electronic databases (Embase, Medline and Google Scholar). Readily accessible peer-reviewed, full articles in English published from December 1st , 2019 to March 26th , 2020 were included. The search terms included combinations of: COVID, SARS-COV-2, glucocorticoids, convalescent plasma, antiviral and antibacterial. There were no restrictions on the type of study design eligible for inclusion. Results As of March 26th, 2020, of the initial manuscripts identified (n=449); forty-one studies were included. These consisted of clinical trials (n=3), case reports (n=7), case series (n=10), retrospective (n=11) and prospective (n=10) observational studies. Thirty-six studies were conducted in China (88%). The most commonly reported medicine in this systematic review was corticosteroids (n=25), followed by Lopinavir (n=21) and Oseltamivir (n=16). Conclusions This is the first systematic review to date related to the therapeutics used in COVID-19 patients. Only 41 research articles on COVID-19 and therapeutics were found eligible to be included, most conducted in China. Corticosteroid therapy was found to be the most studied medicine in the literature.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and lopinavir ritonavir combination: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and lopinavir ritonavir treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute ards respiratory distress syndrome and losartan angiotensin receptor blocker: 1
    • acute ards respiratory distress syndrome and low quality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory and adequate information: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory and lopinavir hiv medication: 1
    • acute respiratory and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and lopinavir ritonavir combination: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and lopinavir ritonavir patient: 1, 2, 3, 4
    • acute respiratory and lopinavir ritonavir treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and losartan angiotensin receptor blocker: 1
    • acute respiratory and low quality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and macau singapore: 1
    • acute respiratory syndrome coronavirus and adequate information: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory syndrome coronavirus and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome coronavirus and lopinavir ritonavir combination: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute respiratory syndrome coronavirus and lopinavir ritonavir patient: 1, 2, 3, 4
    • acute respiratory syndrome coronavirus and lopinavir ritonavir treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome coronavirus and low quality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25